ImageneBio Reports Director/Officer Changes & Compensation Updates
Ticker: IMA · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1835579
| Field | Detail |
|---|---|
| Company | Imagenebio, INC. (IMA) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, officer-appointment, director-election, compensation
TL;DR
ImageneBio swapped execs and directors, updated pay. Big changes coming?
AI Summary
ImageneBio, Inc. filed an 8-K on October 22, 2025, reporting changes effective October 21, 2025. The filing indicates a departure of directors or certain officers, the election of new directors, and the appointment of certain officers, along with updates to compensatory arrangements for these officers. The company, formerly known as Ikena Oncology, Inc., is based in San Diego, California.
Why It Matters
Changes in board and executive leadership can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directorship and officer roles, especially when accompanied by compensation adjustments, can indicate internal restructuring or strategic pivots that carry inherent business risks.
Key Players & Entities
- ImageneBio, Inc. (company) — Registrant
- Ikena Oncology, Inc. (company) — Former company name
- October 21, 2025 (date) — Effective date of changes
- October 22, 2025 (date) — Filing date
- San Diego, California (location) — Company headquarters
FAQ
What specific roles have been affected by the director and officer changes?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but does not specify the exact roles affected in the provided text.
Were there any specific reasons cited for the departure of directors or officers?
The provided text of the 8-K filing does not detail the reasons for any director or officer departures.
What are the new compensatory arrangements for the appointed officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item being reported, but the specific details of these arrangements are not included in the provided excerpt.
When did ImageneBio, Inc. change its name from Ikena Oncology, Inc.?
The date of the name change from Ikena Oncology, Inc. to ImageneBio, Inc. was December 8, 2020.
What is ImageneBio's Standard Industrial Classification (SIC) code?
ImageneBio, Inc.'s SIC code is 2836, categorized under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 11.5 · Accepted 2025-10-22 09:03:11
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IMA The Nasdaq Capital Ma
Filing Documents
- d55570d8k.htm (8-K) — 23KB
- 0001193125-25-245823.txt ( ) — 138KB
- ima-20251021.xsd (EX-101.SCH) — 3KB
- ima-20251021_lab.xml (EX-101.LAB) — 18KB
- ima-20251021_pre.xml (EX-101.PRE) — 11KB
- d55570d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 12526 High Bluff Drive , Suite 345 San Diego , California 92130 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 345-6265 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value IMA The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On October 21, 2025, the board of directors of ImageneBio, Inc. (the "Company") appointed Kristin Yarema, Ph.D., the Company's Chief Executive Officer, as the Company's interim principal financial officer, effective immediately. Dr. Yarema's biographical information is set forth under the section titled "Management" in the Company's registration statement on Form S-1 (File No. 333-290108), filed with the Securities and Exchange Commission on September 8, 2025, and is incorporated herein by reference. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMAGENEBIO, INC. Date: October 22, 2025 By: /s/ Kristin Yarema Kristin Yarema, Ph.D. Chief Executive Officer